This Data Protection Binding Corporate Rules Policy (“Policy”), which forms part of the Novo Nordisk Way of Management, establishes Novo Nordisk’s approach to compliance with European data protection law and specifically to transfers of personal information between the Novo Nordisk entities. This Policy applies to all Novo Nordisk entities and their employees and contains 15 rules (“Rules”). Novo Nordisk must comply with and respect this Policy when collecting and using personal information. This Policy does not replace any specific data protection requirements that might apply to a business area or function. This Policy applies to all personal information of employees, customers, suppliers and other third parties, wherever it is collected and used as part of the regular business activities of Novo Nordisk. Transfers of personal information take place between the Novo Nordisk entities during the normal course of business and such information may be stored in centralised databases accessible by Novo Nordisk entities from anywhere in the world. This Policy will also apply where Novo Nordisk entities process personal information on behalf of other Novo Nordisk entities.
Data protection law gives people the right to control how their
“personal information”1 is used. When Novo Nordisk collects and uses
the personal information of its employees, contractors, business
contacts and other third parties this is covered and regulated by data
Data protection law does not allow the transfer of personal
information to countries outside Europe2 that do not ensure an
adequate level of data protection. Some of the countries in which Novo
Nordisk operates are not regarded by European data protection
authorities as providing an adequate level of protection for
individuals’ data privacy rights.
To avoid breaking the law Novo Nordisk must take proper steps to ensure that its use of personal information on an international basis is safe and, hence, lawful. The purpose of this Policy, therefore, is to set out a framework to satisfy the standards contained in European data protection law and, as a result, provide an adequate level of protection for all personal information used and collected in Europe and transferred from the Novo Nordisk entities within Europe to Novo Nordisk entities outside Europe.
Although the legal obligations under European law apply only to personal information used and collected in Europe, Novo Nordisk will apply this Policy globally, and in all cases where Novo Nordisk processes personal information both manually and by automatic means and whether the personal information relates to Novo Nordisk’s employees, contractors, business contacts or other third parties.3
Central to this Policy are 15 Rules based on, and interpreted in
accordance with, relevant European data protection standards that must
be followed by each employee or contractor when handling personal
information. All Novo Nordisk entities are legally bound to comply
with this Policy.
European data protection law states that Novo Nordisk’s employees, contractors, business contacts and other third parties whose personal information is used and/or collected in Europe and transferred to Novo Nordisk entities outside Europe must be able to benefit from certain rights to enforce the Rules set out in this Policy and these individuals will have the right to:'
In the event of a claim being made in which an individual has suffered damage where that individual can demonstrate that it is likely that the damage has occurred because of a breach of the Policy, Novo Nordisk has agreed that the burden of proof to show that a Novo Nordisk entity outside Europe is not responsible for the breach, or that no such breach took place, will rest with the Novo Nordisk entity responsible for exporting the personal information to that entity outside Europe.
Novo Nordisk A/S has a system in place to oversee and ensure
compliance with all aspects of this Policy. The governance of the
Policy is the responsibility of a corporate compliance support
function reporting to the General Counsel. The corporate compliance
support function is supported by local lawyers at regional and country
level who are responsible for overseeing and ensuring compliance with
this Policy on a day-to-day basis.
If you have any questions regarding the provisions of this Policy,
your rights under this Policy or any other data protection issues you
may contact Novo Nordisk’s corporate compliance support function that
will either deal with the matter or forward it to the appropriate
person or department within Novo Nordisk at the following
Data Protection Officer
Novo Nordisk A/S
DK-2880 Bagsværd Denmark
The corporate compliance support function is responsible for ensuring that changes to this Policy are notified to the Novo Nordisk entities and to individuals whose personal information is processed by Novo Nordisk.
The Rules are divided into two sections. Section A addresses the basic principles of European data protection law Novo Nordisk must observe when Novo Nordisk collects and uses personal information. Section B deals with the practical commitments made by Novo Nordisk to the European data protection authorities in connection with this Policy.
Rule 1 - Novo Nordisk will first and foremost comply with local law where it exists.
As an organisation, Novo Nordisk will always comply with any applicable legislation relating to personal data (e.g. in Denmark, the Danish Act on Processing of Personal Data No.429 of 31 May 2000) and will ensure that where personal information is collected and used this is done in accordance with the local law.
Where there is no law or the law does not meet the standards set out
by the Rules in this Policy, Novo Nordisk’s position will be to
process personal information adhering to the Rules in this
Rule 2A – Novo Nordisk will explain to individuals, at the time their personal information is collected, how that information will be used.
Novo Nordisk will ensure that individuals are always told in a clear
and comprehensive way (usually by means of a fair processing
statement) about the uses and disclosures made of their information
(including the secondary uses and disclosures of the information) when
such information is obtained or, if not practicable to do so at the
point of collection, as soon as possible after that, unless there is a
legitimate basis for not doing so, for example; where it is necessary
to safeguard national security or defence, for the prevention or
detection of crime, taxation purposes, legal proceedings or where
otherwise permitted by law.
Rule 2B – Novo Nordisk will only obtain and use personal information for those purposes which are known to the individual or which are within their expectations and are relevant to Novo Nordisk.
This rule means that Novo Nordisk will identify and make known the
purposes for which personal information will be used (including the
secondary uses and disclosures of the information) when such
information is obtained or, if not practicable to do so at the point
of collection, as soon as possible after that, unless there is a
legitimate basis for not doing so as described in Rule 2A.
Rule 2C – Novo Nordisk will only change the purpose for which personal information is used if Novo Nordisk make people aware of such change or it is within their expectations and they can express their concerns.
If Novo Nordisk collects personal information for a specific purpose
(as communicated to the individual via the relevant fair processing
statement) and subsequently Novo Nordisk wishes to use the information
for a different or new purpose, the relevant individuals will be made
aware of such a change unless there is a legitimate basis for not
doing so as described in Rule 2A above. In certain cases, the
individual’s consent to the new uses or disclosures will be
3A – Novo Nordisk will keep personal information accurate and
up to date.
The main way of ensuring that personal information is kept accurate
and up to date is by actively encouraging individuals to inform Novo
Nordisk when their personal information changes.
Rule 3B – Novo Nordisk will only keep personal information for as long as is necessary.
Novo Nordisk will comply with the Novo Nordisk Procedure for
Document and Record Retention Management (as amended from time to
time) which sets out a set of general requirements for documents and
records applicable globally throughout Novo Nordisk.
Rule 3C – Novo Nordisk will only keep personal information which is adequate relevant and not excessive.
Novo Nordisk will identify the minimum amount of personal information that is required in order properly to fulfil its purpose.
Rule 4A – Novo Nordisk will always adhere to its IT Security Policies.
Novo Nordisk will comply with the requirements in the Computer
Systems Standardisation and Security Procedure as revised and updated
from time to time together with any other security procedures relevant
to a business area or function.
Rule 4B – Novo Nordisk will ensure that providers of services to Novo Nordisk also adopt appropriate and equivalent security measures.
European law expressly requires that where a provider of a service
to any of the Novo Nordisk entities has access to customers’,
contractors, business contacts or employees’ personal information
(e.g. a payroll provider), strict contractual obligations dealing with
the security of that information are imposed to ensure that such
service providers act only on Novo Nordisk’s instructions when using
that information and that they have in place proportionate technical
and organisational security measures to safeguard the personal
Rule 4C- Where Novo Nordisk entities process personal information on behalf of other Novo Nordisk entities those entities will adhere to Rule 4A and act only on the instructions of the Novo Nordisk entity on whose behalf the processing is carried out.
Where a service provider is a Novo Nordisk entity processing personal information on behalf of another Novo Nordisk entity the Novo Nordisk service provider must act only on the written instructions of the Novo Nordisk entity on whose behalf the processing is carried out and ensure that it has in place proportionate technical and organisational security measures to safeguard the personal information.
Rule 5A – Novo Nordisk will adhere to the Subject Access Procedure and will be receptive to any queries or requests made by individuals in connection with their personal information.
Individuals are entitled (by making a written request to Novo
Nordisk) to be supplied with a copy of any personal information held
about them (including both electronic and paper records). Novo Nordisk
will follow the steps set out in the Subject Access Procedure (see
Appendix 1) when dealing with subject access requests.
Rule 5B – Novo Nordisk will deal with requests to delete, rectify or block inaccurate personal information or to cease processing personal information in accordance with the Subject Access Procedure.
Individuals are entitled to rectification, deletion or blocking, as
appropriate, of personal information which is shown to be inaccurate
and, in certain circumstances, to object to the processing of their
personal information. Novo Nordisk will follow the steps set out in
the Subject Access Procedure (see Appendix 1) in such
Rule 6 – Novo Nordisk will not transfer personal information to third parties outside Novo Nordisk without ensuring adequate protection for the information in accordance with the standards set out by this Policy.
In principle, international transfers of personal information to
third parties outside the Novo Nordisk entities are not allowed
without appropriate steps being taken; for example, contractual
clauses (such as the EU standard contractual clauses) which will
protect the personal information being transferred.
Rule 7A – Novo Nordisk will only use sensitive personal information if it is absolutely necessary to use it.
Sensitive personal information is information relating to an
individual’s racial or ethnic origin, political opinions, religious or
other beliefs, trade union membership, health, sex life and criminal
convictions. Novo Nordisk will assess whether sensitive personal
information is required for the proposed use and when it is absolutely
necessary in the context of the business.
Rule 7B – Novo Nordisk will only use sensitive personal information where the individual’s express consent has been obtained unless Novo Nordisk has a legitimate basis for doing so.
In principle, individuals must expressly agree to the collection and
use of sensitive personal information by Novo Nordisk unless Novo
Nordisk has a legitimate basis for doing so. This permission to use
sensitive personal information by Novo Nordisk must be genuine and
Rule 8A – Novo Nordisk will allow customers to opt out of receiving marketing information.
One of the data protection rights that individuals have is the right
to object to the use of their personal information for direct
marketing purposes and Novo Nordisk will honour all such opt out
Rule 8B – Novo Nordisk will suppress from marketing initiatives the personal information of individuals who have opted out of receiving marketing information.
Novo Nordisk will take all necessary steps to prevent the sending of marketing materials to individuals who have opted out.
Rule 9 - Where decisions are made by automated means, individuals will have the right to know the logic involved in the decision and Novo Nordisk will take necessary measures to protect the legitimate interests of individuals.
There are particular requirements in place under European data protection law to ensure that no evaluation of, or decision about, a data subject which significantly affects them can be based solely on the automated processing of personal information unless measures are taken to protect the legitimate interests of individuals.
Rule 10 – Novo Nordisk will provide appropriate training to
employees who have permanent or regular access to personal
information, who are involved in the collection of personal
information or in the development of tools used to
process personal information.
Rule 11 – Novo Nordisk will comply with the Data Protection Binding
Corporate Rules Policy Audit Protocol set out in Appendix
Rule 12 - Novo Nordisk will comply with the Data Protection
Binding Corporate Rules Policy Complaint Handling Procedure
set out in Appendix 3.
Rule 13 – Novo Nordisk will comply with the Data Protection Binding
Corporate Rules Policy Co-operation Procedure set out in Appendix
Rule 14 – Novo Nordisk will comply with the Data Protection Binding
Corporate Rules Policy Updating Procedure set out in
Rule 15A – Novo Nordisk will ensure that where it has reason to believe that the legislation applicable to it prevents it from fulfilling its obligations under the Policy and which has a substantial effect on its ability to comply with the Policy, Novo Nordisk will promptly inform the chief compliance officer unless otherwise prohibited by a law enforcement authority.
Rule 15B – Novo Nordisk will ensure that where there is a conflict between the national law and this Policy the chief compliance officer will make a responsible decision on the action to take and will consult the data protection authority with competent jurisdiction in case of doubt.
1.1 European Data Protection law gives individuals whose personal information is collected and/or used in Europe4 the right to be informed whether any personal information about them is being processed by an organisation. This is known as the right of subject access.
1.2 Individuals whose personal information is collected and/or used in Europe and/or transferred between Novo Nordisk entities under the Novo Nordisk Data Protection Binding Corporate Rules Policy will also benefit from the right of subject access. This Subject Access Procedure explains how Novo Nordisk deals with a subject access request relating to such personal information (referred to as “valid request” in this Procedure).
1.3 Where a subject access request is subject to European data protection law because it is made in respect of personal information collected and/or used in Europe, such a request will be dealt with by Novo Nordisk in accordance with this Procedure, but where the applicable European data protection law differs from this Procedure, the local data protection law will prevail.
1.4 An individual making a valid request to Novo Nordisk is entitled to:
1.4.1 Be informed whether Novo Nordisk holds and is processing personal information about that person.
1.4.2 Be given a description of the personal information, the purposes for which they are being held and processed and the recipients or classes of recipient to whom the information is, or may be, disclosed by Novo Nordisk.
1.4.3 Communication in intelligible form of the personal information held by Novo Nordisk
1.5 The request must be made in writing, which can include email5 .
1.6 Under normal circumstances no fee will be applied
1.7 Novo Nordisk must respond to a valid request within  working days of receipt of that request.
1.8 Novo Nordisk may ask for such information which it may reasonably require in order to confirm the identity of the individual making the request and to locate the information which that person seeks.
2.1 Receipt of a Subject Access Request
2.1.1 If any employee or subcontractor of Novo Nordisk receives any request from an individual for their personal information, they must pass the communication to the local legal and compliance unit immediately upon receipt indicating the date on which it was received together with any other information which may assist the local legal and compliance officer to deal with the request.
2.1.2 The request does not have to be official or mention data protection law to qualify as a subject access request.
2.2 Initial Steps
2.2.1 The local legal and compliance officer will make an initial assessment of the request to decide whether it is a valid request and whether confirmation of identity, or any further information, is required.
2.2.2 The local legal and compliance officer will then contact the individual in writing to confirm receipt of the subject access request, seek confirmation of identity or further information, if required, or decline the request if one of the exemptions to subject access applies.
2.3 Exemptions to subject access
2.3.1 A valid request may be refused on the following grounds;
(a) Where the subject access request is made to a European Novo Nordisk entity and relates to the use or collection of personal information by that entity, if the refusal to provide the information is consistent with the data protection law within that jurisdiction, or;
(b) Where the subject access request does not fall within 2.3.1(a) and;
(i) if, in the opinion of Novo Nordisk it is necessary to do so to safeguard the legitimate business interests of Novo Nordisk, national or public security, defence, the prevention, investigation, detection and prosecution of criminal offences, for the protection of the data subject or of the rights and freedoms of others; or
(ii) if the personal information held by Novo Nordisk is processed by or on behalf of Novo Nordisk solely for scientific purposes or are kept as personal information for a period which does not exceed the period necessary for the sole purpose of creating statistics; or
(iii) if the personal information is held by Novo Nordisk in non-automated form and is not or will not become part of a filing system.
2.4 The Search and the Response
2.4.1 The local privacy compliance officer will arrange a search of all relevant electronic and paper filing systems.
2.4.2 The local legal and compliance officer may refer any complex cases to the Chief Compliance officer for advice, particularly where the request includes information relating to third parties or where the release of personal information may prejudice commercial confidentiality or legal proceedings.
2.4.3 The information requested will be collated by the local legal and compliance officer into a readily understandable format (internal codes or identification numbers used at Novo Nordisk that correspond to personal data shall be translated before being disclosed). A covering letter will be prepared by the local legal and compliance officer which includes information required to be provided in response to a subject access request.
2.4.4 Where the provision of the information in permanent form is not possible or would involve disproportionate effort there is no obligation to provide a copy of the information. The other information referred to in 1.2 above must still be provided. In such circumstances the individual may be offered the opportunity to have access to the information by inspection or to receive the information in another form.
2.5 Requests for deletion, rectification or blocking of personal information
2.5.1 If a request is received for the deletion, rectification or blocking of that individual’s personal information, such a request must be considered and dealt with as appropriate by the local legal and compliance officer.
2.5.2 If a request is received advising of a change in that individual’s personal information, such information must be rectified or updated accordingly if Novo Nordisk is satisfied that there is a legitimate basis for doing so
2.5.3 If the request is to cease processing that individuals’ personal information because the rights and freedoms of the individual are prejudiced by virtue of such processing by Novo Nordisk, or on the basis of other compelling legitimate grounds, the matter will be referred by the local legal and compliance officer to the Chief Compliance Officer to assess. Where the processing undertaken by Novo Nordisk is required by law, the request will not be regarded as valid.
2.6 All queries relating to this policy are to be addressed to the local legal and compliance officer.
The purpose of the Data Protection Binding Corporate Rules Policy
(“Policy”) is to safeguard personal information transferred between
the Novo Nordisk entities. The Policy requires approval from the data
protection authorities in the European member states from which the
personal information is transferred. One of the requirements of the
data protection authorities is that Novo Nordisk audits compliance
with the Policy and satisfies certain conditions in so doing and this
document describes how Novo Nordisk deals with such
2.1 Scope of audit
Novo Nordisk’s Audit Functions will be responsible for performing
the audits ( although from time to time Novo Nordisk may appoint third
party auditors to carry out the audits on its behalf in accordance
with clause 2.4 below) and will ensure that such audits address all
aspects of the Policy, including all IT systems, databases, security
policies, training, privacy policies and contractual provisions in
place within Novo Nordisk in respect of the Policy.
2.2 Responsibility for compliance
Novo Nordisk’s Audit Functions will be responsible for ensuring that
any issues or instances of non-compliance are brought to the attention
of Novo Nordisk’s Executive Management which is committed to ensuring
that any corrective actions take place as soon as is reasonably
Audit of the Policy will take place annually or within a shorter
timescale at the instigation of Novo Nordisk’s Audit Functions. The
scope of the audit performed annually will be decided by Novo
Nordisk’s Audit Functions based on a risk and materiality assessment
which will be updated annually.
Audit of the Policy will be undertaken by Novo Nordisk’s Audit Functions but reliance on work performed by other accredited internal/external auditors may be determined by Novo Nordisk’s Audit Functions. Novo Nordisk’s Audit Functions will manage and provide quality assurance of audit work performed by others.
Novo Nordisk has agreed to provide copies of the results of any audit of the Policy to a European data protection authority of competent jurisdiction upon request subject to applicable law and respect for the confidentiality and trade secrets of the information provided. Novo Nordisk’s Audit Functions will be responsible for liaising with the European data protection authorities for this purpose. In addition, Novo Nordisk has agreed that in data protection authorities may audit the Novo Nordisk entities for the purpose of reviewing compliance with the Policy in accordance with the provisions of clause 5 of the Co-operation Procedure6. Novo Nordisk’s Audit Functions will also be responsible for liaising with the European data protection authorities for this purpose.
The Data Protection Binding Corporate Rules Policy (“Policy”)
safeguards personal information transferred between the Novo Nordisk
entities. The content of the Policy is determined by the data
protection authorities in the European member states from which the
personal information is transferred and one of their requirements is
that Novo Nordisk must have a complaint handling procedure in place.
The purpose of this procedure is to explain how complaints brought by
an individual whose personal information is processed by Novo Nordisk
under the Policy are dealt with.
Individuals can bring complaints in writing by contacting their
local Novo Nordisk legal and compliance unit. Complaints may also be
addressed to the Data Protection Officer via email@example.com.
The local Novo Nordisk legal and compliance unit will handle all
complaints arising under the Policy. The local Novo Nordisk legal and
compliance unit will liaise with colleagues from relevant business and
support units as appropriate to deal with complaints.
Unless exceptional circumstances apply, the Data Protection Officer
will acknowledge receipt of a complaint to the individual concerned
within 5 working days, investigating and making a substantive response
within one month. If, due to the complexity of the complaint, a
substantive response cannot be given within this period, the Data
Protection Officer will advise the complainant accordingly and provide
a reasonable estimate (not exceeding six months) for the timescale
within which a response will be provided.
Certain individuals whose personal information is collected and/or
used and in accordance with European data protection law have rights
under the Policy to complain to a European data protection authority
and/or to lodge an application with a court of competent jurisdiction
if they are not satisfied with the way in which the complaint has been
resolved. Individuals entitled to such rights will be notified
accordingly as part of the complaints handling procedure.
1. This Data Protection Binding Corporate Rules Policy Co-operation Procedure sets out the way in which Novo Nordisk will co-operate with the European7 data protection authorities in relation to the Novo Nordisk Data Protection Binding Corporate Rules Policy (“Policy”).
2. Where required, Novo Nordisk will make the necessary personnel available for dialogue with a European data protection authority in relation to the Policy.
3. Novo Nordisk will actively review and consider:
4. Novo Nordisk will provide upon request copies of the results of any audit of the Policy to a European data protection authority of competent jurisdiction subject to applicable law and respect for the confidentiality and trade secrets of the information provided.
5. Where any Novo Nordisk entity is located within the jurisdiction of a data protection authority based in Europe, Novo Nordisk agrees that that data protection authority may audit that Novo Nordisk entity for the purpose of reviewing compliance with the Policy, in accordance with the applicable law of the country in which the Novo Nordisk entity is located, or, in the case of a Novo Nordisk entity located outside Europe, in accordance with the applicable law of the European country from which the personal information is transferred under the Policy, on giving reasonable prior notice and during business hours, with full respect to the confidentiality of the information obtained and to the trade secrets of Novo Nordisk.
6. Novo Nordisk agrees to abide by a formal decision of the
applicable data protection authority which is final and against which
no further appeal is possible on any issues related to the
interpretation and application of the Policy.
1. This Data Protection Authority Updating Procedure sets out the way in which Novo Nordisk will communicate changes to the Novo Nordisk Data Protection Binding Corporate Rules Policy (“Policy”) to the European8 data protection authorities, data subjects and to the Novo Nordisk entities bound by the Policy.
2. Novo Nordisk will communicate any material changes to the Policy to the Datatilsynet and any other relevant European data protection authorities at least once a year. However, Novo Nordisk does not expect to have to communicate changes to the BCR which are administrative in nature or which have occurred as a result of a change of applicable data protection law in any European country, through any legislative, court or supervisory authority measure unless they result in a substantive change to the BCR. Novo Nordisk will also provide a brief explanation of the reasons for any notified changes to the Policy.
3. Novo Nordisk will communicate any changes to the Policy to the Novo Nordisk entities bound by the Policy and to the data subjects who benefit from the Policy. The Policy contains a change log which sets out the date the Policy is revised and the details of any revisions made.
4. By way of delegated authority from the General Counsel, the
appointed officer will maintain an up to date list of the Novo Nordisk
entities and ensure that all new Novo Nordisk entities are bound by
the Policy before a transfer of personal information to them takes
place. Novo Nordisk will communicate any substantial changes to the
list of Novo Nordisk entities once a year. Otherwise, Novo Nordisk
will communicate an up to date list of entities to the Datatilsynet
and any other relevant European data protection authorities when
In accordance with Clause 7, individuals whose Personal Information is processed by a Novo Nordisk Entity and is subject to the BCR shall be able to enforce the following third party beneficiary rights against the appropriate Exporting Entity (as defined in Clause 7) :